SR-9009 - PharmaQO [60caps/15mg]

SR-9009 Stenabolic Pharmaqo for sale in the UK

SR-9009 by Pharmaqo Labs is an oral research compound, 60 capsules at 15 mg each, studied for endurance, fat oxidation and mitochondrial effects. It is often miscategorised as a SARM but works through a completely different mechanism. To buy SR-9009 UK from a verified source, each batch sold here is lab-tested and shipped same working day from our UK warehouse.

What is SR-9009 (Stenabolic)?

SR-9009, commonly called Stenabolic, is a synthetic agonist of the Rev-Erbα nuclear receptor — not a SARM. It does not bind the androgen receptor and produces no HPTA suppression. Rev-Erbα is part of the body's circadian-clock machinery and a regulator of mitochondrial biogenesis, glucose handling and lipid oxidation. Activating it in rodent studies increased running endurance and shifted fuel use toward fat. Stenabolic was developed by the Scripps Research Institute as a tool to study circadian biology. Oral bioavailability is poor and the active half-life is only around four hours, so research doses must be split across three or four administrations through the day.

SR-9009 Stenabolic benefits

• Endurance research compound — improved running time-to-exhaustion in rodent studies
• Increased mitochondrial density and fatty-acid oxidation in pre-clinical work
• No interaction with the androgen receptor — no HPTA suppression, no PCT required
• No aromatisation, no estrogenic side effects, no hepatotoxicity in available data
• No water retention, no acne, no notable blood-pressure burden

SR-9009 sits in the metabolic/endurance research bucket alongside Cardarine, rather than the muscle-building SARM bucket. Users run it for endurance and conditioning, not mass.

SR-9009 dosage and cycle

Beginners: 10–15 mg/day split into 3–4 doses. Intermediate: 20 mg/day split. Advanced: up to 30 mg/day split. Cycle length typically runs 8–12 weeks. Because the half-life is only ~4 hours, single daily dosing is largely wasted — dose every 3–4 hours during waking hours. Take with a small amount of fat. Avoid dosing close to bedtime.

Side effects and PCT

Long-term human safety data is limited — this is a research compound, not a licensed drug. Reported user effects are generally mild and centre on transient sleep disruption when dosed late, occasional headache, and the inconvenience of frequent dosing. There is no aromatisation and no androgen-receptor activity, so no post-cycle therapy is needed — natural testosterone production is not suppressed. SR-9009 is on the WADA Prohibited List as a metabolic modulator (S4) and must not be used by anyone subject to sport drug testing.

Stacks well with

SR-9009 is most often paired with Cardarine GW-501516 for an endurance-and-fat-loss research stack, since the two compounds work through complementary metabolic pathways. For a recomposition protocol it can be combined with Ostarine MK-2866, or with Clenbuterol in dedicated cutting phases.

Frequently asked questions

How long does SR-9009 take to start working?

Endurance and conditioning effects, where they appear, are typically reported from week 2 onwards as mitochondrial adaptations build. Because the half-life is only around four hours, consistent split dosing across the day from day one is essential — single morning doses are largely wasted plasma-wise.

Is SR-9009 suitable for first-time users?

SR-9009 has no androgenic action and no HPTA suppression, making it mechanically gentler than any SARM or AAS. The main barriers for beginners are the 3–4× daily dosing schedule, poor oral bioavailability, and limited long-term human data.

Can SR-9009 be detected on a drug test?

Standard employment urine screens do not look for SR-9009. It is listed by WADA as a prohibited metabolic modulator (S4), and accredited sport labs can detect it and its metabolites by LC-MS. Anyone subject to sport drug testing should not use this compound.